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Abstract
Background: The development of new anticoagulants is an important goal for the improvement of thromboses treatments.
Objectives: The design, synthesis and experimental testing of new safe and effective small molecule direct thrombin
inhibitors for intravenous administration.
Methods: Computer-aided molecular design of new thrombin inhibitors was performed using our original docking program
SOL, which is based on the genetic algorithm of global energy minimization in the framework of a Merck Molecular Force
Field. This program takes into account the effects of solvent. The designed molecules with the best scoring functions
(calculated binding energies) were synthesized and their thrombin inhibitory activity evaluated experimentally in vitro using
a chromogenic substrate in a buffer system and using a thrombin generation test in isolated plasma and in vivo using the
newly developed model of hemodilution-induced hypercoagulation in rats. The acute toxicities of the most promising new
thrombin inhibitors were evaluated in mice, and their stabilities in aqueous solutions were measured.
Results: New compounds that are both effective direct thrombin inhibitors (the best KI was ,1 nM) and strong
anticoagulants in plasma (an IC50 in the thrombin generation assay of approximately 100 nM) were discovered. These
compounds contain one of the following new residues as the basic fragment: isothiuronium, 4-aminopyridinium, or 2-
aminothiazolinium. LD50 values for the best new inhibitors ranged from 166.7 to .1111.1 mg/kg. A plasma-substituting
solution supplemented with one of the new inhibitors prevented hypercoagulation in the rat model of hemodilution-
induced hypercoagulation. Activities of the best new inhibitors in physiological saline (1 mM solutions) were stable after
sterilization by autoclaving, and the inhibitors remained stable at long-term storage over more than 1.5 years at room
temperature and at 4uC.
Conclusions: The high efficacy, stability and low acute toxicity reveal that the inhibitors that were developed may be
promising for potential medical applications.
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Introduction
Hemostasis is one of the most important processes in organisms,
and disorders in this system cause deaths under a variety of
pathologies. The activation of blood coagulation can be caused by
trauma, sepsis, inflammation, obstetric practice and in the course
of surgical operations, especially operations using extracorporal
blood circulation. Hypercoagulation has also been observed
during infusion therapy with large volumes of crystalloid plasma
substitutes [1,2]. Oral contraception and artificial vessels or
cardiac valves may be sources of minor but permanent activation
of coagulation, eventually exhausting the pool of coagulation
inhibitors and giving rise to thrombotic events.
Thrombotic pathologies are a result of an imbalance in the
activity of thrombin, a key enzyme of the coagulation cascade, and
its natural inhibitors. Overproduction of thrombin may be
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19969countered by the administration of drugs that specifically inhibit
this enzyme.
This simplified conception allows for the design of new drugs
through the development of organic compounds that are inhibitors
for the given target-protein. An ideal inhibitor should be highly
effective and safe, and it should have stable pharmacokinetics that
are only weakly dependent on the patient’s age, sex, concomitant
diseases, drugs and diet. The binding of a compound with plasma
proteins may also interfere with its inhibitory activity. From all
these points of view, synthetic inhibitors with a low molecular
weight are very promising [3]. Thus, a lot of studies have been
directed towards the discovery of effective and safe small molecule
anticoagulants that act via direct thrombin inhibition. However,
despite considerable attention in this area, only one synthetic
direct thrombin inhibitor (DTI), argatroban [4], is currently in use
for intravenous administration in medicine. Dabigatran etexilat
was approved recently as the first small molecule thrombin
inhibitor for peroral introduction [5]. Thus, the development of
effective new direct thrombin inhibitors is a very important
objective for the improvement of anticoagulant therapy.
This study presents the results of our search for new small
molecule thrombin inhibitors for intravenous administration.
New inhibitor design is one of the key phases of the long and
expensive process of developing new drugs. The structures of
thrombin and many of its complexes with a diverse set of
experimental inhibitors have been resolved by X-ray structure
analysis, and many of these 3D structures have been submitted to
the Protein Data Bank (PDB) [6]. This information, together with
modern methods of structure-based drug design, can be used to
shorten the discovery and design phases of new drug development
concerning by completing a search for new inhibitor structures.
Thethrombinactivesite hasthreepockets(Fig.1).The negatively
charged residue of aspartic acid (Asp 189) is situated on the bottom
of the deep and narrow pocket S1. The two others pockets, S2 and
S3, have hydrophobic surfaces. The S2 pocket contains proline and
glycine residues, while Leu99, Ile174, and Trp215 residues are
situated in the S3 pocket. The S3 pocket binds predominantly to
aromatic residues of substrates (or inhibitors) and is thus referred to
as the aryl-binding site. Usually, the inhibitor’s moieties, located in
each of the enzyme active site pockets, are denoted P1, P2 and P3,
according to the pocket number. A scheme showing the disposition
of inhibitor residues in the thrombin active site is depicted in Fig. 2,
using the example of the well-known orcinol-based thrombin
inhibitor, which is very similar to new inhibitors developed in this
study. This scheme is based on data from the X-ray structure
analysis (PDB, code 1T4U) [7].
Virtual screening by means of ligand docking is widely
recognized as a helpful approach in modern drug design. We
performed computer-aided molecular design employing our own
docking program and used the strategy of stepwise experimental
screening for the estimation of antithrombin and anticoagulant
activities of the compounds with the best scoring functions.
Important characteristics, such as acute toxicity and the stability of
new inhibitors during long-term storage, were also determined.
This combined approach allowed us to shorten the first phase of
the search for new thrombin inhibitors and to develop for a period
less than 1 year new effective and safe promising drug candidates
for medical applications.
Materials and Methods
1. Materials
Donor blood was collected at the Blood Transfusion Station
of the National Research Center for Hematology and was used
without identifiers. Blood was collected into 3.8% sodium
citrate (pH 5.5) at a blood/anticoagulant ratio of 9/1. Platelet
poor plasma (PPP) for endogenous thrombin potential mea-
surements was prepared by centrifuging blood for 15 min at
1500 g.
Human thrombin (8.3 mg/ml) was obtained from Hematologic
Technologies Inc. (Essex Junction, VT, USA). The thrombin-
specific chromogenic substrate Tosyl-Gly-Pro-Arg-p-nitroanilide
(identical to Chromozym-TH) was purchased from Sigma (St.
Louis, MO, USA). Thrombin-specific fast (BOC-Ala-Pro-Arg-
AMC) and slow (BOC-Ile-Gly-Arg-AMC) fluorogenic substrates
[8], where BOC is the tert-butoxycarbonyl residue and AMC is the
7-amino-4-methylcoumarine residue, were synthesized in the
Institute for Medical and Biological Chemistry (Moscow, Russia).
Cremophore EL (macrogol-36-glycerol-ricinoleat) was purchased
from Caelo (Caesar & Loretz GmbH, Hilden, Germany), and
standard normal saline was purchased from Juno, a medical
holding company (Medsynthesis Ltd., Novouralsk, Russia). All
other domestic chemicals of reagent and analytical grade were
used without further purification.
2. Methods
2.1. A computer-based search for new thrombin
inhibitors. The docking studies were performed using our
docking package SOL software implemented in the program
complex KeenBASE [9]. The main features of this package are as
follows: a rigid target-protein structure, with the active site
represented by a set of grids for different type of potentials to
describe protein-ligand interactions (electrostatic and Van der
Waals (VdW) forces) in the frame of the Merck Molecular Force
Field (MMFF94) [10]; a rigorous description of solvation and
desolvation effects upon ligand binding, based on the generalized
Born approximation [11,12], which is included in the set of
potential grids; a genetic algorithm for global optimization of
Figure 1. The thrombin active site surface and the pockets of
the active site (Sn). The blue color corresponds to nitrogen atoms,
red to oxygen atoms, yellow to sulfur atoms, dark grey to carbon atoms
and light grey to hydrogen atoms.
doi:10.1371/journal.pone.0019969.g001
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strain energy in terms of MMFF94.
To perform docking with the SOL program for ligands of any
protein, the preprocessing of protein and respective ligands has to
be carried out. Usually there are incomplete side chains and
missing amino acid residues in structure of the protein in the
vicinity of the binding site. In our study missing protein hydrogen
atoms were added with the Reduce program [13]. All water
molecules, inhibitors and small residues, like sulfates and
phosphates, were removed from the complexes. Next, all protein
atoms were typified in accordance with the Merck Molecular
Force Field (MMFF94) [10] using our own procedure [14]. The
docking area was represented by a cube with a 22 A ˚ edge covering
the protein active site. The cube center was chosen as the
geometrical centre of the native ligand of the respective PDB
protein-ligand complex, and the protein structures were saved to
mrk files that were suitable for subsequent 10161016101 grid
generation.
The grid of potentials representing thrombin-ligand interactions
was calculated separately using the SOL_GRID program [9],
before the initiation of the docking procedure. Throughout the
docking studies, all ligands were considered fully flexible – i.e., all
topologically available torsional degrees of freedom were unfrozen
and allowed to rotate freely, directed only by ligand internal
energy preferences in the frame of MMFF94. Bond lengths and
valence angles were frozen in the course of the docking procedure.
The careful validation of the SOL docking program was carried
out using two different validation protocols to test the correctness
of the physical and mathematical principals implemented in this
docking program [9,15]. The first protocol concerns the
identification of active ligands among a mixed set of active and
inactive ones. The second protocol [16] concerns the determina-
tion of accuracy for positioning ligands in proteins active sites. This
protocol was used to compare the two docking programs, SOL
and the standard AutoDock 3.05. The first protocol showed a
good to excellent quality in the SOL program for the selection of
active inhibitors for four different target-enzymes from a large set
of active and inactive (‘‘rubbish’’) ligands [9]. The accuracy of
ligand positioning in the active sites of enzymes was defined by the
root mean square deviation (RMSD) between ligand docked poses
and experimental ligand poses taken from the Protein Data Bank
[17]. The results of the docking quality comparison for both
programs demonstrated that the docking quality of SOL is better
than that of AutoDock 3.05, if we consider docking quality with
the criterion RMSD,1.5 A ˚. Almost twice as many native ligands
docked by SOL had a RMSD#1A ˚ when compared to the
respective number of ligands docked by AutoDock 3.05 [9].
The thrombin 3D structure was taken from the Protein Data
Bank (PDB, code 1O2G). All possible ligand poses within 22 cubic
angstroms around the center of the thrombin active site were
considered in docking. Electrostatic, VdW and solvation-desolva-
tion potentials were calculated on a 10161016101 grid inside this
cube. Parameters of the genetic algorithm (population size 30000,
mating pool size 70, number of generation 300, number of runs
50, and parameters for definition of elitism, mutation, crossover,
niching) [9] were chosen to get the best docking results for the
native ligand of the 1O2G PDB complex and for the thrombin-
argatroban complex (1DWC PDB complex) with an accuracy of
1.5 A ˚.
Three-dimensional structures of ligands (thrombin inhibitor
candidates) for initial virtual screening experiments with com-
pounds received from the National Cancer Institute (NCI) were
taken directly from the NCI Diversity set of compounds [18]. The
next steps of the virtual screening were performed with our
specially designed virtual ligand libraries. 3D structures of ligands
constructed during the hit optimization process were generated by
means of the CORINA 3D structure generation service [19].
Virtual screening was performed using a massive-parallel super-
computer using X-Com grid technology, developed at the
Research Computer Center of Moscow State University [20,21].
Visual inspection of ligand poses within the thrombin active site,
depicted as Solvent Excluded Surfaces (SES), was performed with
the help of the TAGSS program for triangulated SES construction
and visualization [22].
2.2. Measurement of thrombin induced hydrolysis of
specific substrates. The kinetics of thrombin inhibition was
determined from the hydrolysis reaction of a specific substrate by
thrombin in the presence of the tested substances. The
chromogenic substrate (Tosyl-Gly-Pro-Arg-p-nitroanilide) or fast
fluorogenic substrate (BOC-Ala-Pro-Arg-AMC) was used.
Plate wells were filled with 20 mM HEPES (pH 8.0) containing
140 mM NaCl and 0.1% polyethylene glycol (molecular weight
6000 Da). Thereafter, substrate was sequentially added to each
well (final concentration, 100 mM), followed by the substance
being tested (to a final concentration that was varied) and
thrombin (final concentration, 0.2 nM). The hydrolysis rate was
monitored spectrophotometrically at 405 nm (absorption maxi-
mum of the reaction product – p-nitroaniline), or fluorometrically
(lex=380 nm; lem=440 nm for fluorescent reaction product 7-
amino-4-methylcoumarine).
The initial rate was determined as the slope of the linear portion
of the kinetic curve over the first 10 to 20 min of measurement.
The inhibitory effect was expressed as the percentage reduction of
the initial hydrolysis rate. The reaction rate in the absence of
Figure 2. Scheme of disposition of ligand moieties (Pn) in the thrombin active site. One of the known orcinol-based thrombin inhibitors [7]
is presented. The active site pockets (Sn) are indicated.
doi:10.1371/journal.pone.0019969.g002
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parallel determinations.
The inhibitor concentration was determined decreasing hydro-
lysis rate to 50% (IC50). Values of the inhibition constants were
calculated on the assumption about competitive mechanism of
inhibition using equation (1)
KI~IC50= 1zS=KM ðÞ , ð1Þ
where: KI - the constant of inhibition,
S - the concentration of a substrate (100 mM),
KM - the Michaelis constant of a specific substrate for
thrombin (9.44 mM, average from ref. [23,24] and our
measurements for chromogenic and 13 mMf o rt h e
fluorogenic substrate [8], respectively).
2.3. Thrombin generation test. The kinetics of thrombin
generation in plasma was monitored using a modification of the
standard method [25] using a slow fluorogenic substrate BOC-Ile-
Gly-Arg-AMC [8]. Normal donor plasma (PPP) was placed in the
wells (90 ml/well) of a 96-well flat-bottom microtiter plate, after
which 10 ml of the substance solution to be tested was added in
different concentrations, along with 10 ml of the slow fluorogenic
substrate (initial concentration 5 mM). In the control wells (without
inhibitor), 10 ml of the solvent used was added (20 mM HEPES,
pH 7.5 and 140 mM NaCl; or pure ethanol, or dimethylsulfoxide
(DMSO) for different substances). The samples were incubated at
37uC for 3–5 min before being activated with thromboplastin,
which was a 1:250 dilution of a standard prothrombin time reagent
(Renam, Moscow, Russia) in the same buffer supplemented with
90 mM CaCl2. The final concentration of tissue factor during
activationwas about 4 pM.Thromboplastin (25 ml)was added to all
wells simultaneously using a multichannel micropipette. The
moment of thromboplastin addition was taken as time zero. The
kinetics of accumulation of the fluorescent reaction product 7-
amino-4-methylcoumarine (AMC) was recorded for 65 min with a
fluorometric Fluoroscan II reader (LabSystem, Finland)
(lex.=380 nm; lem.=440 nm). The results were averaged over
two parallel samples. The error ofparallel measurements was within
2–5%. At every moment, the rate of product accumulation is
proportional to the instant thrombin concentration present in
plasma.Therefore,thecurveforthetemporalevolutionofthrombin
in the system may be obtained using differentiation of the curve for
AMC accumulation. For each sample, arbitrary fluorescence units
were converted to absolute AMC concentrations using the
calibration signal obtained by adding a known AMC
concentration into each particular plasma sample in the presence
of the fluorogenic substrate and the tested substance. The
corrections were done taking into account the substrate
consumption and the nonlinearity of the AMC calibration curve.
The area under the thrombin time curve over a period of 60 min
(endogenous thrombin potential, ETP) was determined.
The standard method for the measurement of thrombin
generation assumes plasma sample dilution. We have shown
before [26] that the ETP value depends on the level of dilution.
Because it is especially important for the study of hemodilution, we
have developed a modification of the thrombin generation test that
excludes additional dilution of the samples during measurement.
In particular, 200 ml of PPP samples were placed in the wells of
a 96-well plate. Then, 2 ml of a solution of fluorogenic substrate
BOC-Ile-Gly-Arg-AMC in DMSO (initial concentration 41 mM)
was added, and coagulation was triggered by 3 ml of activator,
which was a 1:20 dilution of a standard prothrombin time reagent
(Renam, Moscow, Russia) in the buffer (20 mM HEPES, 140 mM
NaCl, pH 7.5) supplemented with 1.4 M CaCl2. Measurement of
fluorescence (120 min) and processing of the results obtained were
carried out by the methods described earlier.
2.4. Experimental study of the new thrombin inhibitor 4i in
vivo using model of hemodilution-induced hypercoagulation
in rats. The study was approved by the Ethics Committee of the
Center for Theoretical Problems of Physicochemical Pharmacology
(Permit Number: 21-04-2009). The housing and operating
conditions for animals strictly satisfied the requirements of the
Guide for Care and Use of the Laboratory Animals [27]. All efforts
were made to minimize suffering in animals.
The anticoagulation activity of one of the new thrombin
inhibitors (4i) was studied in vivo in a newly developed model of
hemodilution-induced hypercoagulation in rats. Experiments were
carried out on male outbred white rats weighing 250–450 g and
housed in a vivarium. A polyethylene cannula was implanted into
the right femoral artery of the rats, which were anesthetized with
thiopental (40 mg/kg of body weight, i.p.), to a depth of 4–5 cm.
Blood loss (23.064.5% of estimated blood volume) and hemodi-
lution with plasma-substituting solution (PSS) were simulated by
fast blood sampling (4.5 ml during approximately 1 min) and
bolus administration of an equal volume of either normal saline
(control group) or normal saline supplemented with 2 mM of the
thrombin inhibitor (experimental group). Coagulation was ana-
lyzed in samples of blood collected before hemodilution for all
animals. Blood samples for repeated analysis were taken from each
animal only once at 10, 30 or 60 min after the PSS infusion. The
coagulation system status before and after PSS infusion was
investigated by endogenous thrombin potential measurement. The
volume of blood loss was calculated on the assumption that the
total blood volume of the rat is equal to 6.5% of the body weight.
2.5. Measurement of the acute toxicity of new compounds
in mice. Preliminary safety examination for the best synthesized
inhibitors was carried out by measuring their acute toxicity in
C57Bl/6 mice (females, 26–28 g, intraperitoneal administration)
[28]. The total number of animals used in each experiment was
20–35. The dose of inhibitor that caused mortality in half of the
animals after 2 or less hours (LD50) was determined. The solution
of inhibitor (initial concentrations ranged from 50 to 7 mg/ml
depending on substance solubility) in normal saline supplemented
with 20% of cremophore EL to improve the inhibitor’s solubility
was administered to animals intraperitoneally. For administration
of different doses of an inhibitor, different volumes of the initial
stock inhibitor solution were supplemented with corresponding
volumes of vehicle (20% cremophore EL in normal saline) to
obtain a constant administered volume of 1.8 ml in each case. To
obtain the highest doses of inhibitors, the animals were injected
with 2.3 ml of stock inhibitor solutions instead. Preliminary results
showed that after the administration of 2.3 ml of normal saline
supplemented with 20% cremophore EL, animals did not have
any toxic manifestations.
2.6. Stability of inhibitors in solution. Activities of the best
new thrombin inhibitors were measured by the inhibition of
chromogenic substrate hydrolysis (see section 2.2) during long-
term storage in physiological saline (1 mM solutions) at room
temperature and at 4uC. All solutions were sterilized before
storage by autoclaving (120uC, 1 atm, 20 min).
Results
1. Design of new thrombin inhibitors
Nonpeptide thrombin inhibitors based on an orcinol scaffold
have been described in the literature. In spite of their structural
New Synthetic Direct Thrombin Inhibitors
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the order of several tens of nM) and have sufficient selectivity
towards thrombin [29–32]. In this study, we tried to improve the
potency of such inhibitors. We used traditional orcinol core and
benzenesulfonic acid residues as the P2 and P3 fragments of the
inhibitor molecules but varied the basic P1 moiety and the length
of the linker between the P1 moiety and the aromatic P2 fragment
of the compounds. In addition, we examined compounds with
different substituents in the benzenesulfonic acid fragment (R1 and
R2 in P3). The basic structure of the new compounds is presented
in Fig. 3A.
The first step of our search for new P1 moieties was a virtual
screening of the existing positively charged ligands from the NCI/
DTP Open Chemical Repository (National Cancer Institute, USA)
[18],includingthewholeoftheNCIDiversitySet[33].Compounds
from the NCI library wereused in the very beginning of the study to
try out and debug a docking program and to adjust it to thrombin.
Given that those compounds had already been synthesized by that
time andwerekindlygiftedtousbytheNCI, wehad anopportunity
of not only calculating their scoring functions with our docking
program, but also measuring their real (not virtual) inhibitory
potencies experimentally. More than 2000 compounds were
virtually screened and as a result 114 virtual lead substances were
selected for subsequent experimental verification. These com-
pounds were obtained from NCI. The criteria for the hits selection
were sufficiently negative SOL scoring function (represented as
predicted protein-ligand binding energy ,25.5 kcal/mol) and
reasonable ligandposes inthe thrombinactivesite, verifiedby visual
inspection. Among these 114 compounds, 15 proved to be real
thrombin inhibitors in our experimental tests with specific thrombin
substrates. Five compounds had sufficiently high activities to be
interesting for subsequent drug design. Four of these compounds
possessedanisothiuroniumgroupintheP1positionofthe molecule,
which has never been used as a P1 moiety in a thrombin inhibitor
molecule before (Fig. 4 and Table 1). The high activity and reduced
basicity of isothiouronium vs. traditional guanidinium derivatives
make the isothiouronium residue an interesting possibility for the
design of new thrombin inhibitors.
Taking into account the data in the literature and the results
obtained during computer-based and experimental screening of
ligands from NCI, we attempted to construct new chemical
structures that should be effective thrombin inhibitors. As
mentioned before, the known residues of orcinol and benzene-
sulfonic acid were selected as P2 and P3 inhibitor fragments,
respectively, but different basic P1 fragments were examined.
Computer-based screening of more than 6000 compounds gave
evidence of possible inhibitory compounds with 4-aminopyridi-
nium (4-AP), isothiuronium (IT) or 2-aminothiazolinium (2-AT)
fragments in the P1 position of the ligands (Fig. 3B). The SOL
scoring functions of many of these compounds were sufficiently
negative. The last type of moiety that was studied was the
‘‘reversed’’ and constrained analog of isothiouronium. The
examples of the scoring functions for some compounds with
different P1 fragments are presented in Table S1.
Theoretical calculation showed that an increase in the linker
length between the P1 and P2 fragments in molecules of IT and 4-
AP derivatives should give rise to a less negative scoring function.
This is clearly illustrated in Table 2 for a series of 4-AP
compounds with different linker lengths. Introduction of different
R1 and R2 substitutes in the aromatic ring of the P3 fragment
modified the scoring function, sometimes noticeably, but we could
not identify any regularity in these changes (Table S2).
2. The experimental examination of new compounds
Some of the aforementioned new compounds were synthesized
on a 0.25–2.5 g scale via a 2 to 4 step strategy. The schemes of the
compounds’ syntheses are depicted in Fig. 5. Details of these
syntheses are described in [34] and in the Text S1. All compounds
have been numbered according to the course of preparation.
Compounds 1a–b, 2a–j, and 3a–j served as intermediates in the
syntheses of the final inhibitors. These compounds are presented
only in the descriptions of the Text S1. As Table 3 contains only
the most promising new inhibitors, some other final compounds
(inhibitors 5, 6, and 7a–d) are described only in the Text S1 and
are presented in Table S2. The chemical structures of all new
inhibitors were confirmed by
1H-NMR data (see the Text S1).
Figure 3. The newly developed thrombin inhibitors. (A) – The common structural formula of new compounds. (B) – The most effective
fragments P1 obtained in this study.
doi:10.1371/journal.pone.0019969.g003
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systems in vitro and the anticoagulant activity in plasma in vitro were
determined using the thrombin generation test. One of these new
inhibitors (4i) was investigated in an in vivo rat model of
hemodilution-induced hypercoagulation.
3. Inhibitory activity of new substances towards
thrombin in buffer system
All new compounds inhibited the hydrolysis of the specific
substrate by thrombin in a dose-dependent manner, achieving
total inhibition at some concentrations (Fig. 6A). Similar patterns
of behavior are usually typical for competitive inhibitors. Table 3
presents the constants of thrombin inhibition for the best of the
newly developed inhibitors. These constants were calculated from
the measured IC50 values with the assumption of a competitive
type of inhibition. Data for argatroban are presented in Table 3
for comparison [35]. Similar data for other newly synthesized
compounds are presented in Table S2. As a result, several
compounds of IT, and especially of the 4-AP series, were shown to
be the most active orcinol-based thrombin inhibitors. Some of
these compounds were the most active from known low molecular
weight DTIs with KI in the sub-nanomolar range.
4. Anticoagulant activity of new inhibitors in plasma in
vitro
Anticoagulant activity of an inhibitor in plasma is dependent
not only on its constant of inhibition, but also on possible
interactions with other components of the coagulation system and
on binding with plasma proteins, especially with albumin.
Therefore, in the next step of experimental testing, we examined
Figure 4. Structures of the five best compounds received from NCI. NCI ID numbers are indicated.
doi:10.1371/journal.pone.0019969.g004
Table 1. The SOL scoring functions and the results of experimental measurements of thrombin inhibitory activity for the five best
compounds received from NCI (see Fig. 4).
NCI ID SOL scoring function, kcal/mol Inhibition of specific thrombin substrate hydrolysis in buffer system
IC50, mM (substrate used)
1) KI, mM
2)
NSC 305831 26.14 72 (SCHR)6 . 2
NSC 4482 26.21 3.45 (SFLUO)0 . 4
NSC 41339 26.25 240 (SFLUO) 27.6
NSC 328131 26.39 ,35
3) (SFLUO)4 . 0
NSC 123477 26.41 75 (SFLUO)8 . 6
1)The chromogenic (SCHR), or fast fluorogenic (SFLUO) specific thrombin substrate was used.
2)Values of KI were calculated assuming a competitive mechanism of inhibition.
3)This substance has slow inhibition kinetics. The KI value was calculated using the end point of the inhibition for each concentration of inhibitor.
doi:10.1371/journal.pone.0019969.t001
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system new compounds. It was shown by the thrombin generation
test that these compounds reduced ETP in plasma. The value of
reduction increased with an increasing concentration of the
inhibitor (Fig. 6B). Additional concentrations that decreased ETP
by 50% (IC50 for ETP reduction) are also presented in Tables 3
and S2.
Although the IC50(ETP)/KI ratio for new compounds was high,
the best compounds had IC50 values for ETP reduction that were
below the corresponding value seen in argatroban (0.6–0.97 mM)
[36,37]. Thus, the best of the designed compounds could have
great potential for in vivo studies and subsequent medical
applications in the injection form.
5. Acute toxicity of new thrombin inhibitors
A preliminary study of the best newly synthesized inhibitors
acute toxicity was performed, and the safety of these compounds
was evaluated in vivo. The results obtained are presented in Table 3.
The acute toxicity (LD50) in mice for several of the new inhibitors
proved to be lower than that for clinically used argatroban [38]
(Table 3).
6. Stability of the inhibitors in aqueous solutions
All new inhibitors selected for long-term storage were stable
after sterilization by autoclaving. The activities of the most
effective new thrombin inhibitors remained stable after storage in
Table 2. Examples of scoring function values for compounds
with constant a P1 part, but a different length of the linker (n)
between the P1 and P2 fragments of a molecule
1).
The length of the linker (n) 1 2 3 4 5
Scoring function, kcal/mol 27.50 26.57 26.48 26.27 25.45
1)The common formula for these compounds is depicted in Fig. 3A. R1 and R2
are H, R (in P1 position) is residue of 4-AP.
doi:10.1371/journal.pone.0019969.t002
Figure 5. Synthetic scheme of the new orcinol-based thrombin inhibitors. Reagents: (stage 1) BrCH2(CH2)nCl, K2CO3, (CH3)2CO or CH3CN,
reflux, 36–43 h; components of reaction mixture were used for subsequent reactions without purification of individual ingredients; (stage 2)
RPhSO2Cl, Et3N, THF, stirring, 20–25uC, 7 h or ArSO2Cl, PyH, 20–25uC, 3 days then 60uC, 2 h; (stage 3) NaI, (CH3)2CO or CH3CN, reflux, 48 h; (stage 4)
corresponding nucleophile dioxane, 80uC, 2 days or reflux, 20 h.
doi:10.1371/journal.pone.0019969.g005
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at room temperature and at 4uC. As an example, activities of
compound 4i during long-term storage are presented in Fig. 6C.
7. Model of hemodilution-induced hypercoagulation in
rats
The rat hemodilution-induced hypercoagulation model was
developed for testing the effectiveness of new inhibitors in vivo.
Previously we have shown that plasma dilution with crystalloid
solutions in vitro intensified coagulation, whereas the addition of a
thrombin inhibitor to the solution partially neutralized that effect
[26,39]. In this work, we applied the same approach to
hemodilution in vivo. Animals with 23.064.5% blood loss were
infused with an equal volume of either standard saline (control
group) or of saline supplemented with 2 mM of the new inhibitor
4i (experimental group). The changes of the endogenous thrombin
potential (ETP) with respect to its initial level for the control and
experimental groups at different times after infusion are presented
in Fig. 5D. The results obtained showed that animals infused with
normal saline developed hypercoagulation that increased with
time, whereas the presence of the thrombin inhibitor in the PSS
canceled the hypercoagulation effect of hemodilution in the
experimental group.
Discussion
A fast decrease of preformed thrombin activity rises is vital in
acute situations. Thus, it is reasonable in such cases to
intravenously administer direct thrombin inhibitors to block
hypercoagulation as quickly as possible. Our aim was to design
new thrombin inhibitors for intravenous administration, whereby
inhibitors can get directly to blood plasma where thrombin works.
Thus, bioavailability was not an issue, and we were not restricted
to ligands with low basicity in their P1 fragments.
We have shown before that moderate plasma dilution in vitro (up
to 2–2.5 times) with different artificial PSS produced hypercoa-
gulation changes in the coagulation system (the ETP and spatial
clot growth rate were increased) [26,39]. This fact suggests that
plasma dilution, especially by crystalloid PSS, could also be a risk
factor for the induction of thrombotic states during moderate
hemodilution in vivo. The development of hypercoagulation has
been shown to correlate with the infusion of large volumes of
crystalloid solutions in patients [1,2]. At present, the mechanism of
this phenomenon is not clear; however, many investigators
propose that during moderate hemodilution, the coagulation
system is more sensitive to decreasing concentrations of coagula-
tion inhibitors than to dilution of procoagulant factor precursors
that are present in the blood in abundance.
To prevent the development of hemodilutional hypercoagula-
tion, we supplemented a crystalloid PSS with DTI [26,39]. It was
shown that the natural thrombin inhibitor antithrombin III could
be used for this purpose [39]. However, this inhibitor is isolated
from human plasma and is thus very expensive and not completely
safe with regard to the transmission of viral infections. Small
molecule synthetic thrombin inhibitors are more suitable for this
purpose. To be used in PSS, these inhibitors should be not only
highly effective and safe, but also stable in aqueous solutions. The
development of this kind of inhibitor was one of the objectives of
our study.
A majority of successful thrombin inhibitors have positively
charged or neutral but easy polarizable (e.g. containing halogen
atoms) P1 fragments (Fig. 2). During thrombin-inhibitor complex
formation, the P1 moiety of the inhibitor is located in the
thrombin active site within a narrow cavity, exposing the carboxyl
side chain of the Asp189 residue on its bottom (S1 pocket in Fig. 1
and Fig. 2).
The severe spatial restrictions dictate the small size and
hydrophobic nature of the P2 inhibitor position. In contrast, the
restrictions on the P3 site are not as stringent because the
corresponding binding site in the thrombin molecule is broad and
exposed to the solvent. This feature gives also us the opportunity to
modify the part of the P3 moiety, which is projected into the
Table 3. Parameters of thrombin inhibition and acute toxicity for the best new thrombin inhibitors and argatroban
1).
N
2) RR 1 R 2
KI for thrombin inhibition in
buffer system
3,4),n M
IC50 for reduction of
thrombin generation in
plasma, mM
LD50 (mouse),
intraperitoneal
administration, mg/kg
4e 4-AP -F -H 0.3 0.1 523.1692.3
4f 4-AP -Cl -H 0.21 0.26 679.06152.7
4g 4-AP -SO2CH3 -H 0.75 0.16 166.7620.0
4h 4-AP -H -Cl 0.78 0.15 372.7684.6
4i 4-AP -H -H 0.78 0.25 418.9633.0
8b IT -SO2CH3 -H 1.5 0.80 .458.0
5)
8c IT -Cl -H 0.33 0.16 793.56118.5
8d IT -H -H 0.95 0.90 .1111.1
8f IT -F -H 2.03 1.24 .653.1
5)
8h H3C-NH-IT
6) -Cl -H 5.7 0.53 .287.0
5)
Argatroban
7) 39 0.65 475
1)The common formula for all inhibitors is depicted in Fig. 3A.
2)Synthesis details are in the Supporting Information.
3)Measured by chromogenic substrate Tosyl-Gly-Pro-Arg-p-nitroanilide.
4)The KI values were calculated with the assumption of a competitive type of inhibition. The KM value of the substrate for thrombin is 9.44 mM.
5)Substance is nontoxic in thousand-fold ETP reduction IC50 dose (per whole mouse).
6)IT contains methyl group as a substituent in one of the amino groups.
7)All constants for argatroban (except for the LD50) were measured and were in good agreement with data in the literature [35–38].
doi:10.1371/journal.pone.0019969.t003
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modify, for example, its solubility and lipophilicity characteristics.
The selection of effective ligands for the inhibition of a target
enzyme is usually a very laborious, long and expensive process.
Computer-aided screening using well adjusted docking program
allowed us to shorten this stage of the study. Adjustment of our
program, SOL, for the thrombin inhibitor search was executed
during a screening of the NCI database, because we compared
actual inhibitory activities of these compounds to their scoring
functions in our theoretical calculations. As a result, five new
inhibitor molecules were discovered. Besides, while screening
compounds from NCI, we discovered that some compounds with
an isothiuronium group in the P1 position of the ligand were
sufficiently effective thrombin inhibitors. Currently, this moiety
has not been used as a fragment in the P1 position of thrombin
inhibitors.
In the next stage of the study, we generated large virtual
libraries of ligands as possible thrombin inhibitors, taking into
account all discovered patterns. We focused on variations of basic
fragments in the P1 position and on a search for the optimal linker
length connecting this fragment with the residue in the P2 position
of inhibitor. As was mentioned before, the orcinol and
benzenesulfonic acid residues were selected as P2 and P3
fragments of our new inhibitors, respectively. Existing inhibitors
containing these fragments are pictured in Fig. 7 [29–32]. These
inhibitors were selected for modification because they are
relatively simple, sufficiently effective (KI in the nM range) and
highly selective. The overall number of compounds studied in
virtual screening experiments was near 6000. These calculations
have shown that the introduction of a 4-aminopyridinium (4-AP),
isothiuronium (IT), or 2-aminothiasolinium (2-AT) group in the P1
position of the compound (Fig. 3B) should give rise to a high
inhibitory activity. According to these calculations, the inhibitory
effectiveness should improve when the length of the linker between
the P1 and P2 fragments of the inhibitor molecule decreases from
5t o1C H 2 groups (Table 2).
Several series of new compounds were synthesized to experi-
mentally confirm the accuracy of these theoretical conclusions.
Their inhibitory activity was first checked in different experimental
procedures in vitro.
The direct antithrombin activity of new compounds was
confirmed by the measurement of the inhibitory effect on the
hydrolysis rate of specific chromogenic substrate in the presence
of a constant concentration of thrombin in a buffer system. All
of the synthesized compounds decreased substrate hydrolysis
rate in a dose-dependent manner. The results of one of such
experiment are presented in Fig. 6A. However, antithrombin
activity is insufficient to make these new compounds actual
anticoagulants in plasma. The anticoagulation activity of an
inhibitor in plasma is dependent not only on its inhibition
Figure 6. Examples of some typical results obtained during experimental testing of new inhibitors. (A) – Inhibition of thrombin-induced
chromogenic substrate hydrolysis in buffer systems by different concentrations of 8c. (B) – Reduction of endogenous thrombin potential in plasma
by increasing concentrations of 8d. (C) – Stability of thrombin inhibitory activity of 4i (1 mM) during long-term storage in physiological solution at 4uC
or at room temperature. (D) – Influence of physiological solution (control group) or of this PSS supplemented with 2 mMo f4i (experimental group)
on the development of hypercoagulation in models of hemodilution-induced hypercoagulation in rats. The changes of the ETP values are presented
relatively to basic level in different times after PSS infusions. * - The differences were considered as statistically significant (P,0.05, Student’s t-test,
n=6–10).
doi:10.1371/journal.pone.0019969.g006
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of the coagulation system and on binding with plasma proteins,
especially albumin. We used a thrombin generation test for the
characterization of coagulation in plasma. Endogenous throm-
bin potential (ETP) is one of the parameters of this test. ETP is
the total quantity of active thrombin arising in plasma after
standard coagulation activation. It is equal to the area under the
thrombin kinetic curve. The presence of additional thrombin
inhibitors in the plasma sample should change the thrombin
formation and inhibition kinetics. As a result, ETP should
decrease. All new inhibitors significantly decreased ETP. The
effect value also increased with an increasing concentration of
the inhibitor, and at some concentrations, thrombin generation
was completely inhibited (Fig. 6B).
Thus, the results obtained show that these new compounds are
effective thrombin inhibitors and have high anticoagulant activity
in plasma in vitro. Moreover, these inhibitors excellently retain
activity after long-term storage in aqueous solutions (Fig. 6C). For
the best new compounds, the effectiveness (KI,1 nM; minimal
IC50 for ETP reduction, 0.1 mM) and stability in aqueous solutions
was better than for argatroban (Tables 3 and S2).
Experimental screening showed that our inhibitors with new P1
fragments were highly effective. Inhibitory efficacy was much
greater for compounds with a linker length of n=2 as compared to
n=3. The SOL scoring function correctly estimated that 4-AP
and IT derivatives with a 2 carbon chain linker between the basic
P1 group and the orcinol core (n=2 in Tables 3 and S2) should be
more potent than the derivatives with a 3 carbon chain linker
(n=3), although the magnitude of this difference is underestimated
by the SOL score (Table S2). Because of the small number of 2-
AT derivatives synthesized, we do not present a similar
dependence for these compounds.
Theoretical calculations predicted sufficient differences in
scoring functions for compounds with different R1 and R2
substituents in the P3 fragment of inhibitor molecule. In spite of
this, the results obtained showed that, with the exception of the p-
CH3 substituent, introduction of different substituents in the ring
of benzenesulfonic acid had a relatively weak influence on KI and
IC50 values for ETP reduction (Table S2).
Hence, according to a comparison of the experimental testing
results withthe theoreticalpredictionofthepowerof new inhibitors,
we conclude that our docking program is excellent in searching for
ligands with an effective basic fragment P1, and it correctly presents
the tendency of inhibitor efficacy to change according to linker
length. However, it is not suitable for the fine analysis of the
effectiveness of structures with different substituents in the
benzenesulfonic acid group in the P3 position of a molecule.
The examination of acute toxicity shows that the LD50 values of
the new inhibitors are comparable, and sometimes even higher,
than those seen for the clinically used argatroban (Table 3). In
addition, toxic effects appear in doses 2000–5000 times higher than
the appropriate therapeutic dose. Also, the new compounds appear
to be very stable during long-term storage in aqueous solutions.
After examining the new inhibitors’ effectiveness, stability and
safetyinacuteexperiments,the anticoagulantefficacyoneofthe new
compounds (4i) was also studied in vivo in a model of hemodilutional
hypercoagulation in rats. It was demonstrated experimentally that
the hypercoagulant state has developed in vivo after the infusion of a
sufficiently large volume of crystalloid PSS. Similar to in vitro
experiments [26], the introduction of direct thrombin inhibitor in
PSS canceled this effect completely (Fig. 6D). The inhibitor selected
for these experiments (4i)h a sa nI C 50 value for reduction of ETP in
vitro equal to 0.25 mM. We supposed that after in vivo administration,
this inhibitor could be accumulated in different organs and tissues.
The inhibitor can be also partially consumed after the initiation of
coagulation. Therefore, a 2-mM concentration of the inhibitor was
selected for supplementation of PSS inexperiments. It isnecessary to
note that the selected inhibitor concentration turned out to be too
high. It should be decreased, if the aim was to return the ETP to the
normal initial value. Therefore, this inhibitor was very effective after
intravenous administration in vivo.
The DTIs that were developed are very suitable for intravenous
administration. However, it is obvious that the development of new
anticoagulants for peroral introduction is also a very important
objective for the amelioration of antithrombotic therapy, especially
prophylactic therapy. The main problem of these treatments is low
bioavailability of the DTIs using this type of administration. One
possible solution of this problem is the development of prodrugs. In
these compounds, the active parts of inhibitor molecules are
protected by special groups that are removed, leading to formation
of the active inhibitor directly in the body after passing through the
mucous membrane of the gastrointestinal tract [40]. We suppose
that our new inhibitors could be a good basis for the development of
such proinhibitors, and their application will not be restricted to
only intravenous administration.
Figure 7. The known orcinol-based thrombin inhibitors
described in the literature [29–32].
doi:10.1371/journal.pone.0019969.g007
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augmented by experimental screening, is a powerful strategy to
find new inhibitor motifs and to improve the potency of inhibitors.
We developed new effective, stable, and safe thrombin inhibitors.
Furthermore, these inhibitors not only slow down coagulation in
different tests in vitro, but they also prevent the appearance of a
hypercoagulant state in models of hemodilutional hypercoagula-
tion in rats in vivo. These compounds are very promising, but
further detailed studies are necessary to confirm the possibility of
medical applications for these new inhibitors.
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